Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...

Hyperglycemia

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In Support of Venous Glucose as a Reference Matrix for Evaluating Continuous Glucose Monitoring Accuracy.

Journal of diabetes science and technology·2026

Same author

User Experiences of a Bihormonal Fully Closed-Loop System Among Adults with Type 1 Diabetes in a Real-World Setting: A Qualitative Analysis.

Diabetes technology & therapeutics·2025

Same author

Dementia Risk in People With Type 1 Diabetes and Associated Risk Factors: A Nationwide, Register-Based Cohort Study.

Diabetes care·2025

Same author

Sex-based disparities in perceived versus objective glycaemic control in type 1 diabetes: a cross-sectional cohort study.

The lancet. Diabetes & endocrinology·2025

Same author

Oral Glucose-Lowering Agents and Large-for-Gestational-Age Infants in Gestational Diabetes-Reply.

JAMA·2025

Same author

Biosimilar insulins: Narrative review of the regulatory framework and registration studies.

Diabetes, obesity & metabolism·2025

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Human Pseudoislet System for Synchronous Assessment of Fluorescent Biosensor Dynamics and Hormone Secretory Profiles

Human Pseudoislet System for Synchronous Assessment of Fluorescent Biosensor Dynamics and Hormone Secretory Profiles

Published on: November 3, 2023

Glucose sensing issues for the artificial pancreas.

J Hans DeVries¹

¹Academic Medical Centre, Amsterdam, The Netherlands. j.h.devries@amc.uva.nl

Journal of Diabetes Science and Technology

|November 4, 2009

Summary

Continuous glucose monitoring (CGM) accuracy is crucial for artificial pancreas systems. This review examines CGM readiness, accuracy assessment, optimal sensor placement, and delays impacting closed-loop development.

Keywords:

artificial pancreas closed loop continuous glucose monitoring

More Related Videos

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Human Pseudoislet System for Synchronous Assessment of Fluorescent Biosensor Dynamics and Hormone Secretory Profiles

Human Pseudoislet System for Synchronous Assessment of Fluorescent Biosensor Dynamics and Hormone Secretory Profiles

Published on: November 3, 2023

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Area of Science:

Biomedical Engineering
Medical Device Technology
Endocrinology

Background:

Continuous Glucose Monitoring (CGM) technology has evolved significantly since its market introduction in 1999.
The advent of real-time data transmission from CGMs raises questions about their integration into advanced diabetes management systems.
Closed-loop systems, or artificial pancreases, require highly accurate and reliable glucose readings for effective operation.

Purpose of the Study:

To evaluate the current accuracy of continuous glucose monitoring (CGM) systems for potential use in prototype artificial pancreas systems.
To explore methodologies for assessing CGM accuracy in the context of closed-loop diabetes management.
To determine optimal spatial and temporal parameters for CGM function relative to insulin delivery sites, considering physiological and instrumental delays.

Main Methods:

Retrospective analysis of continuous glucose monitoring (CGM) system performance.
Discussion of established and proposed methods for CGM accuracy assessment.
Review of literature concerning the impact of sensor-to-infuser distance and system delays on closed-loop performance.

Main Results:

Current CGM accuracy is a critical factor in determining suitability for artificial pancreas prototypes.
Standardized methods for CGM accuracy assessment are essential for reliable performance evaluation.
The proximity of the CGM sensor to the insulin infusion site and inherent system delays can significantly affect closed-loop control efficacy.

Conclusions:

The readiness of current CGM technology for seamless integration into artificial pancreas systems requires rigorous validation of accuracy and performance.
Further research into optimal sensor placement and mitigation of physiological and instrumental delays is necessary to advance closed-loop diabetes technology.
Addressing these challenges will pave the way for more effective and safer automated insulin delivery systems.